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Antigen variation is a successful defense system
adopted by several infectious agents to evade the host
immune response. The principle of this defense strategy
in the African trypanosome paradigm involves a dense
packing of variant surface glycoproteins (VSG) exposing
only highly variable and immuno-dominant epitopes to
the immune system, whereas conserved epitopes be-
come inaccessible for large molecules. Reducing the size
of binders that target the conserved, less-immunogenic,
cryptic VSG epitopes forms an obvious solution to com-
bat these parasites. This goal was achieved by introduc-
ing dromedary Heavy-chain antibodies. We found that
only these unique antibodies recognize epitopes com-
mon to multiple VSG classes. After phage display of
their antigen-binding repertoire, we isolated a single
domain antibody fragment with high specificity for the
conserved Asn-linked carbohydrate of VSG. In sharp
contrast to labeled concanavalin-A that stains only the
flagellar pocket where carbohydrates are accessible be-
cause of less dense VSG packing, the single domain
binder stains the entire surface of viable parasites, irre-
spective of the VSG type expressed. This corroborates
the idea that small antibody fragments, but not larger
lectins or conventional antibody fragments, are able to
penetrate the dense VSG coat to target their epitope.
The diagnostic potential of this fluorescently labeled
binder was proven by the direct, selective, and sensitive
detection of parasites in blood smears. The employment
of this binder as a molecular recognition unit in im-
muno-toxins designed for trypanosomosis therapy be-
comes feasible as well. This was illustrated by the spe-
cific trypanolysis induced by an antibody::-lactamase
fusion activating a prodrug.
Several infectious agents, e.g. human immunodeficiency vi-
rus, Hepatitis, Plasmodium, and Trypanosomes, have acquired
a system of antigenic variation to circumvent the immune
response of their host (1–4). The paradigm of this defense
mechanism can be found in the African trypanosomes (4–6).
The key player in their antigenic variation mechanism is the
variant-specific surface glycoprotein (VSG)1 dimer of which 107
identical copies form a dense layer covering the entire surface
of the unicellular parasite (7, 8). At regular time intervals a
new VSG type appears on the surface of the parasite, prevent-
ing recognition of the parasites by an upcoming anti-VSG re-
sponse directed against the previous VSG type. Obviously, the
trypanosomes possess a vast repertoire of VSG genes and mul-
tiple diversification mechanisms to express one VSG after the
other so that only one type is expressed at the time (5, 9, 10).
The comparison of the primary structures of VSGs taking
into account the position and number of conserved cysteine
residues and N-glycosylation sites revealed the presence of
three VSG subclasses represented by AnTat 1.1 (class I), MITat
1.1 (class II), and MITat 1.5 (class III) (11, 12). However, even
VSGs belonging to the same subclass expose only unique and
immunogenic regions to the solvent when present on the coat of
the parasite (13–15). Therefore, trypanosomes have adopted a
strategy of actively forcing the immune system to produce
antibodies against regions that change continuously. Conse-
quently, most monoclonal antibodies raised against VSG recog-
nize a determinant with an accessible location on the parasite
(13, 14). Isolation of a monoclonal antibody with a pan-reactivity
toward multiple VSGs on viable parasites appears to be far more
challenging, because the conserved epitopes become cryptic upon
the assembly of VSGs on the membrane of the parasite. To be
effective as an anti-trypanosome agent it seems that molecules
are required that infiltrate the dense VSG coat to reach a con-
served epitope common to the majority of the VSG molecules. The
VSGs contain such conserved epitopes, e.g. an Asn-linked high
mannose oligosaccharide (GlnNAc2-Man5–9) is conserved among
all VSG of Trypanosoma brucei brucei subspecies (16). This par-
ticular carbohydrate epitope should be a preferred target to de-
sign specific drugs because it is absent from glycoproteins of the
parasite host (17).
To circumvent the inaccessibility of the conserved epitopes
we introduced dromedary antibodies. The serum of Camelidae
contains a high proportion of functional antibodies devoid of
light chains (18). The antigen-binding fragment of these so-
called heavy-chain antibodies (HCAbs) is comprised in one
single domain of only 15 kDa. This dedicated variable domain
referred to as VHH is the smallest intact antigen-binding frag-
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ment derived from bona fide antibodies (19). After immuniza-
tion of dromedaries, or llamas, antigen-specific single domain
VHHs can easily be isolated by the use of the phage-display
technology (19–21). Because VHHs are about 10 smaller than
conventional antibodies it is tempting to speculate that these
recombinant antibody fragments exhibit a more efficient VSG
coat-penetrating capacity and reach epitopes that are inacces-
sible for conventional antibodies. In addition, it has been re-
ported that the antigenic regions for VHHs or HCAbs on a
protein are different from those for the antigen-binding site
of conventional antibodies (20, 21). This aspect, together with
their smaller size, suggests that VHHs constitute a yet unex-
plored pool of candidates to target new epitopes such as those
scattered on the surface of living trypanosomes that are
non-antigenic or inaccessible for conventional antibodies. The
benefits of VHHs in this respect should not only be limited
to African trypanosomes but could be extended to include other
infectious agents relying on an active antigenic variation
mechanism (1–3).
Here we report on the isolation of a VHH, specific for the
conserved carbohydrate epitope of VSGs. Unlike other, larger
molecules, it is shown that this VHH penetrates the dense VSG
coat of the living parasite and stains trypanosomes independ-
ent of the expressed VSG class. The efficacy of this antibody
fragment as a small molecular recognition unit in a more com-
plex construct opens promising routes to develop new diagnos-
tic and therapeutic tools to combat trypanosomosis. An illus-
trative example is included of how this might be accomplished.
EXPERIMENTAL PROCEDURES
Purification of VSG AnTat 1.1, MITat 1.1, MITat 1.5, and Deglyco-
silated VSG—Frozen stabilates of Trypanosoma brucei brucei blood-
stream parasites expressing the respective VSG were expanded by
infection of rats (Charles River). Rats with systemic parasitaemia (typ-
ically 4–5 days post infection) were exsanguinated, and parasites were
purified from heparinized blood by DEAE-cellulose (DE52, Whatman)
chromatography. VSG was isolated via ion-exchange chromatography
and gel filtration (7, 22). Deglycosilated AnTat1.1 was prepared by
incubating 100 g VSG for 16 h at 30 °C with 10 units of N-glycosi-
dase-F (Roche Applied Science). Deglycosilated protein was recovered
from the flow-through of the sample passed over concanavalin-A col-
umn (Amersham Biosciences) equilibrated with PBS and was further
purified by gelfiltration.
Dromedary Immunization—A dromedary (Camelus dromedarius) re-
ceived six injections of 1 mg VSG AnTat 1.1 at weekly intervals (20). 45
days after the first injection serum was collected and separated into its
different IgG subclasses by differential adsorption on HiTrap-Protein-A
and HiTrap-Protein-G columns (Amersham Biosciences) as described
previously (21). At the same time, anti-coagulated blood was collected to
isolate lymphocytes with Uni-Sep (Sopagen). Peripheral blood lympho-
cytes were counted, and aliquots of 5  106 cells were pelleted and
stored at 80 °C until further use.
Dot-blot Analysis—Each VSG (2 g) (AnTat 1.1, MITat 1.1 or MITat
1.5) was spotted onto a nitrocellulose membrane and dried, and residual
protein-binding sites were blocked for 2 h with PBS with 1% (w/v)
bovine serum albumin. The membrane was incubated sequentially with
one of the fractionated dromedary IgG isotype (5 g/ml in PBS), a rabbit
anti-dromedary IgG serum, and a goat anti-rabbit-IgG antibody conju-
gated to horseradish peroxidase (Sigma). In between the successive 2 h
incubations was a washing step with PBS-0.1% Tween 20. Thirty min-
utes after adding the substrate (methanol/4-chloro-1-nafthol in PBS/
H2O2) the reaction was stopped by washing the membrane with water.
Solid-phase Binding ELISA—Different VSG (AnTat 1.1, deglycosi-
lated AnTat 1.1, MITat 1.1, or MITat 1.5) at 1 g/ml 0.1 M NaHCO3, pH
8.2, were coated overnight (4 °C) to 96-well plates. Residual protein-
binding sites were blocked (2 h, room temperature) with 1% casein in
PBS. After incubation with serial dilutions of dromedary IgG sub-
classes, bound dromedary IgG was detected with a rabbit anti-drome-
dary IgG serum and a goat anti-rabbit IgG antibody conjugated to
alkaline-phosphatase (Sigma). Ten minutes after addition of the sub-
strate p-nitrophenyl phosphate (Sigma), the optical density was meas-
ured at 410 nm.
The carbohydrate specificity of our VHHs was tested by ELISA.
Wells of peptide immobilizer plates (SanverTech) were coated overnight
(4 °C) with oligomannose-9 (Oxford Glycoscience) (0.1 g/ml 0.1 M
NaHCO3, pH 8.2). Overcoating was omitted and the VHH (in triplicate)
was loaded in 1:2 serial dilutions starting at 10 g/ml. Bound VHH was
detected using a mouse anti-His antibody and a goat anti-mouse IgG
antibody conjugated to horseradish peroxidase. Thirty minutes after
adding peroxidase substrate, the reaction was stopped with 0.1 N
H2SO4 and the optical density was measured at 450 nm (690 nm was
used as reference filter).
For the concanavalin-A competition experiment, we coated VSG An-
Tat 1.1 (1 g/ml 0.1 M NaHCO3, pH 8.2) overnight at 4 °C on 96-well
plates. Residual protein-binding sites were blocked for 2 h at room
temperature with 1% casein in PBS. The VHH (starting from 10 g/ml,
in triplicate) was serially diluted in PBS or 50 g concanavalin-A/ml
PBS and applied to the wells. Detection of bound VHH was as for the
carbohydrate ELISA.
VHH Library Construction and Selection of Binders—The prepara-
tion of mRNA from lymphocytes, cDNA generation, VHH amplification
(with oligo-dT primers), and cloning into a phage-display vectors was
performed as described (21). Retrieval of VSG specific VHHs was done
by three consecutive rounds of panning on antigen immobilized at 10
g/well in microtiter plates (21). After the last panning individual
colonies were picked and expression of the VHH gene was induced with
1 mM isopropyl -D-thiogalactopyranoside. The recombinant VHH, ex-
tracted from the periplasm, was tested for antigen recognition
by ELISA.
Construction of the cAb-An33::-lactamase Conjugates—The
cAb-An33::-lactamase conjugate was constructed by PCR amplifica-
tion, and insertion of the cAb-An33 sequence, the llama 2c hinge
sequence, and the -lactamase gene followed by a His6 tag between the
NcoI and EcoRI sites of pHEN4 vector (20, 21). Firstly, the particular
his-tagged -lactamase was amplified from Enterobacter cloacae P99
strain (23) by PCR using primers “L forward” (5-CATGCCATGGGC-
ACGCCAGTGTCAGAAA AA-3) and “L reverse” (5-CGCGAATTCT-
TAATGATGATGATGATGATGCTGTAGCGCCTCGAGG-3) (restric-
tion sites underlined) and ligated as a NcoI-EcoRI fragment into pH-
EN4. Secondly, the cAb-An33 gene linked to the llama 2c hinge gene
(19) was engineered as a NcoI-NcoI fragment using primers “A4Short
forward” (5-CATGCCATGACTCGCGGCCCAGCCGGCCATGGC-3)
and “CEAMH reverse” (5-CATGCCATGGGAGCTTTGGGAGCTTTGG-
AGCTGGGGTCTTCGCTGTGGTGCGCTGAGGAGACGGTGACCTGG-
GT-3) (restriction sites underlined) encoding the 15-amino acids-long
llama 2c hinge (AHHSEDPSSKAPKAP). The plasmid containing the
cAb-An33 gene, as obtained after the pannings, was used as template.
The PCR fragment was digested by NcoI and ligated in the expression
vector containing the -lactamase gene, linearized by NcoI.
Expression and Purification of Single Domain Antibodies and Con-
jugates—VHH genes of the clones that scored positive in ELISA were
recloned into an expression vector pHEN6 as NcoI-BstEII fragments
(21).
Production and purification of recombinant antibody fragments and
of the cAb-An33::-lactamase conjugate was performed as described
(21, 24). Recombinant protein was  95% pure as evaluated by Coo-
massie-stained SDS-PAGE. The absorption at 280 nm of the fractions
and the extinction coefficient, as calculated from the amino acid se-
quence, were used to determine the protein concentration.
Immunofluorescent Microscopy and Flow Cytometry Analysis—The
VHH, polyclonal rabbit antibodies and cAb-An33::-lactamase conju-
gate were FITC-labeled (25), and the amount of labeling was deter-
mined spectrophotometrically. The bloodstream-form of T. brucei brucei
(AnTat 1.1, MITat 1.1, and MITat 1.5) was used in immunofluorescent
microscopy and flow cytometric analysis. Aliquots of 107 parasites were
incubated for 30 min in an ice-bath with 10% normal rabbit serum/PBS
prior to adding different FITC-labeled VHHs (5 g), FITC-labeled poly-
clonal rabbit anti-VSG, or FITC-labeled concanavalin-A (Sigma) (5 g/
ml). After 30 min the parasites were pelleted and extensively washed
with PBS/10% normal rabbit serum to remove unbound antibodies and
analyzed in FACSvantage Fluorescence-Activated Cell Sorter (BD Bio-
sciences) or by immunofluorescence microscopy (Nikon ECLIPSE E600
with phase contrast, 40–100 magnification). Two l DAPI staining
(Roche) was added to 10 l sample prior to microscopic imaging with the
corresponding filter. The same field was imaged with the FITC filter
and both images were superimposed.
Trypanolysis Assay—Purified parasites (106 parasites/ml phosphate-
saline-glucose buffer) incubated with TNF- (104 units/ml) were moni-
tored for 6 h. The experiment was repeated in absence or presence of
cAb-An33 or cAb-An04 (1 g/ml) added to the parasite culture 1 h prior
to TNF- addition. The data shown are typical results from 3 independ-
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ent experiments performed in triplicate (average standard deviation
1–2%).
Cytotoxicity Assays—The LD50 of the phenylenediamine mustard
parental drug (PDM) and the 7-(4-carboxibutamido)-cephalosporin
mustard prodrug (CCM) were determined by incubating 106 T. brucei
brucei AnTat 1.1 parasites (2.5 h, 30 °C) in phosphate-saline-glucose
buffer with PDM or CCM (0–150 M) (26).
To test the toxic effect of the VHH conjugated to -lactamase and
prodrug we incubated 106 T. brucei brucei AnTat 1.1 or MITat 1.5
parasites with 5 g cAb-An33::-lactamase (1 h, 4 °C). After washing off
unbound material, various concentrations of CCM were added and the
surviving parasites were counted. This experiment was repeated 7
times in triplicate, and congruent results were obtained (standard
deviation of 1%, according to t test analysis).
RESULTS
Identification of VSG-specific VHHs—A dromedary and a
rabbit were immunized with VSG purified from T. brucei brucei
AnTat 1.1. The conventional antibody subclass (i.e. the IgG1),
and the HCAb subclasses (i.e. IgG2 and IgG3) were fraction-
ated from the dromedary serum (18, 21). These fractionated
dromedary IgGs and the rabbit anti-AnTat 1.1 serum were
used in a dot-blot assay to evaluate their capacity to recognize
epitopes shared by the three different VSG classes (I-III), rep-
resented by AnTat 1.1, MITat 1.1, and MITat 1.5, respectively
(11, 12) (Fig. 1A). The conventional antibodies from rabbit and
dromedary, as well as the HCAb of the IgG2 class, all recognize
epitopes on the VSG AnTat 1.1 and MITat 1.5. Remarkably, the
HCAbs of the IgG3 isotype bind all three VSG classes to a
similar extent. Hence other parts of the immunogen (AnTat
1.1) seem to be antigenic for the IgG3. Moreover, from the
signal intensity it is inferred that the dromedary IgG3 isotype
contains a detectable titer of antibodies that associate with
epitopes common to VSGs of different classes.
Because the antigen-binding fragment of a dromedary HCAb
is comprised within one single domain (i.e. the VHH) it was
decided to isolate these small molecular recognition units via
recombinant phage-display technology. The VHH repertoire
present in an aliquot of 5  107 lymphocytes was cloned in a
phage-display vector (20, 21, 27). Pannings of this VHH library
with immobilized AnTat 1.1 yielded seven VSG-specific VHHs
(GenBankTM accession numbers AY263485-AY263491). All
these VHH genes encoded the framework-2 hallmark amino
acids that distinguish the variable domain of a heavy chain of
a HCAb from that of a conventional antibody (19). These seven
VHHs were produced in Escherichia coli, purified, and their
specificity and possible cross-reactivity with other VSGs was
analyzed on AnTat 1.1, MITat 1.1, MITat 1.5, and deglycosi-
lated AnTat 1.1 via solid-phase ELISA (Fig. 1B). Five VHHs
recognize AnTat 1.1, independent of its glycosilation status,
but fail to bind the MITat 1.1 and MITat 1.5. These VHHs are
probably directed against unique epitopes present in the hy-
pervariable region of AnTat 1.1. Interestingly, two VHHs, the
cAb-An02 and cAb-An33, associate with all three VSG mole-
cules. However, the antigen-binding capacity of the former is
hardly influenced upon deglycosilation of the antigen, whereas
the latter interacts poorly with the deglycosilated AnTat 1.1.
Carbohydrate Specificity of cAb-An33—The binding proper-
ties of cAb-An33 were further analyzed because it is better
expressed than cAb-An02, gives higher signals in ELISA, and
seems to recognize the carbohydrate moiety of VSG, a part of
the molecule that is expected to be solvent accessible in the
trypanosomal coat. The carbohydrate specificity of cAb-An33
was confirmed by competition with lectins, by inhibition of
TNF- trypanolysis, and by direct binding to VSG peptide
fragments or oligosaccharides.
First, the binding curves of a serial dilution of the cAb-An33
from 10 to 0.01 g/ml in a solid-phase ELISA with coated
AnTat 1.1 are indicative for an affinity in the nM range. The
binding is, however, competed by the presence of concanava-
lin-A (Fig. 2A), a lectin known to bind the carbohydrates at-
tached to VSG (28). Because a direct interaction between the
cAb-An33 and concanavalin-A could not be demonstrated in an
ELISA approach nor by biosensor, it is clear that the lectin
competes specifically with the antibody fragment for its
epitope. The association of any other VSG-specific VHH with
AnTat 1.1 is not impeded by an excess concanavalin-A.
Second, the interaction of TNF- and the carbohydrate moi-
ety of the VSG, probably that exposed in the flagellar pocket,
induces rapid lysis of parasites (29, 30). This in vitro TNF--
mediated T. brucei AnTat 1.1 lysis is effectively inhibited by
the presence of cAb-An33 (Fig. 2B). It is a specific inhibition
because the co-incubation of TNF- with any of the other VSG-
specific VHH, e.g. cAb-An04, failed to protect the trypanosomes
from lysing. There is no indication for a TNF- and cAb-An33
interaction, so the antibody fragment and the area harboring
the lectin-like activity of TNF- compete with each other for
the same target.
Third, from all peptides fractionated after digesting AnTat
1.1 with various proteases (30), only the fractions containing
peptides carrying carbohydrates (revealed by orcinol staining)
give a signal in a direct ELISA with cAb-An33.
Finally, in a direct ELISA, only the cAb-An33 binds signifi-
cantly to oligomannose-9, a complex carbohydrate structure
resembling the Asn-linked oligomannose of trypanosomes (16).
In contrast, all other VSG-specific VHHs failed to interact with
this oligomannose-9 as exemplified by cAb-An46 in Fig. 2C.
Interaction of VSG Carbohydrate-specific VHHs with Living
Trypanosomes—The capacity of cAb-An33 to recognize its
epitope on living trypanosomes was analyzed via flow cytom-
etry and microscopy. Flow cytometry shows that FITC-labeled
cAb-An33 stains parasites of the three VSG classes, although
not to the same intensity (Fig. 3A). However, the labeling
intensity is always much larger than that obtained with FITC-
labeled concanavalin-A. In contrast, the variant specific VHH
(e.g. cAb-An46) labeled with FITC stains only parasites ex-
pressing AnTat 1.1 (Fig. 3B). The variants expressing VSGs of
FIG. 1. Antigen specificity of rabbit and dromedary IgGs and
dromedary VHHs. A, dot-blot analysis of polyclonal rabbit IgG and
camel conventional antibodies (IgG1) and heavy-chain antibodies (IgG2
and IgG3) on VSGs of different classes, i.e. AnTaT 1.1, MITat 1.1, and
MITat 1.5. B, ELISA signals on AnTat 1.1, deglycosilated AnTat 1.1,
MITat 1.1, and MITat 1.5 obtained with different recombinant VHHs
retrieved from pannings of the “immune VHH library.”
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other classes are not stained, and the profile is indistinguish-
able from an unstained sample of parasites, or trypanosomes
incubated with an antibody fragment of non-VSG specificity.
Thus, it seems that cAbAn-33, like concanavalin-A, detects
various T. brucei parasites. Both proteins bind to the same
sugars of the VSG (as inferred from Fig. 2A), however, they do
so to a different extent as seen by immuno-fluoresence micros-
copy. The FITC-labeled concanavalin-A stains only the flagel-
lar pocket of parasites (green spots, Fig. 3D), adjacent to the
nucleus (blue DAPI-stained spot, Fig. 3D). Apparently, the Asn-
linked carbohydrates of VSG are only accessible for the 90 kDa
large lectin when located in the flagellar pocket (28). In con-
trast, the FITC-labeled cAb-An33 stains the entire surface of
the parasite (Fig. 3C). Hence, the cAbAn-33 succeeds in target-
ing its carbohydrate epitope even when present in the dense
VSG coat of living parasites where access for larger molecules
is seriously limited.
Due to the high fluorescence intensity and the high selectiv-
ity of cAb-An33 for the trypanosomal carbohydrates, it becomes
possible to visualize the trypanosomes directly in blood smears
(Fig. 3, E–F). Such a selective staining can certainly never be
achieved with concanavalin-A because its broad recognition of
sugars would stain the cells of the host of the parasite as well,
and the weak labeling signal of the trypanosomal flagellar
pocket would remain unnoticed.
Efficacy of cAb-An33 as Molecular Recognition Unit in a
Bifunctional Construct—The single domain nature of the cAb-
An33 makes it particularly suitable as modular building block
into larger, more complex constructs (24), e.g. to generate an
immuno-toxin. To address this possibility, we genetically
linked the genes for this small, molecular recognition unit that
specifically targets living trypanosomes with that of -lacta-
mase. The kcat/Km values of the -lactamase for nitrocefin were
determined at 1.1  107 M1 s1 for both, the free and the
conjugated form, reflecting that the linkage to the antibody
fragment does not hinder the catalytic activity of the enzyme.
The antigen-binding capacity of the cAb-An33 moiety in the
conjugate was confirmed in a direct ELISA on coated AnTat1.1,
and with nitrocefin as chromogenic substrate (31). Thus, both
the binding of the VHH and the enzymatic activity of the
-lactamase are well preserved in the fusion protein. The -lac-
tamase can also convert the mustard (CCM) into the highly
toxic PDM (26). A 2.5 h incubation of 0 to 150 M CCM to
bloodstream form T. brucei AnTat 1.1 parasites in PSG buffer
revealed an LD50 value of 20 M for this prodrug, which is 20
higher than the parental drug PDM (Fig. 4). The sub-lethal
doses of CCM (0.5–10 M) become highly toxic for the trypano-
somes when added to parasites washed extensively after a
prior incubation with the cAb-An33::-lactamase fusion. This
indicates that sufficient enzyme remains attached by virtue of
the trypanosome-specific antibody to generate the more toxic
PDM from CCM. A similar result was obtained with trypano-
somes that express the MITat 1.5, confirming that the broad
trypanosome specificity of the cAb-An33 moiety is maintained
in the conjugate. This prodrug activation is immunologically
specific because exposing the parasites to a non-binding control
conjugate cAb-Lys3::-lactamase prior to CCM treatment is
well tolerated by trypanosomes (Fig. 4) (cAb-Lys3 is a well
studied VHH with specificity for chicken lysozyme (27, 32)).
DISCUSSION
A dromedary, single domain antibody-fragment with speci-
ficity for the Asn-linked carbohydrate of the trypanosomal VSG
FIG. 2. Carbohydrate specificity of
cAb-An33. A, ELISA of cAb-An33, seri-
ally diluted in PBS (ConA curve) or in
excess of concanavalin-A (ConA curve)
before applying the mixture to AnTat 1.1-
coated wells. B, trypanolysis assay in
which the fate of purified trypanosomes
was followed for 6 h when incubated with
TNF- (dotted line, f), or with TNF- and
cAb-An33/ml (Œ), or with TNF- and cAb-
An04 (ƒ). C, ELISA of cAb-An33 () and
another AnTat 1.1-specific VHH (cAb-
An46, E) on oligomannose-9.
FIG. 3. Staining of living trypanosomes. Fluorescence-activated
cell sorter results with FITC-labeled cAb-An33 (A) or cAb-An46 (B) on
purified trypanosomes expressing AnTat 1.1 (solid line), MITat 1.1
(dotted line), or MITat 1.5 (dashed line). The profiles of the dotted and
dashed lines overlap each other in B. C, immuno-microscopy of FITC-
labeled cAb-An33 on purified trypanosomes expressing AnTat 1.1. The
trypanosomes were stained with DAPI staining to visualize the nu-
cleus. D, same as C but the cAb-An33 was replaced by FITC-labeled
concanavalin-A. The nucleus (N) and the flagellar pocket (FP) of one
trypanosome are indicated (arrows). E and F, blood of a trypanosome
infected mouse incubated with FITC-labeled cAb-An33 illuminated
with visible light (E) or UV (F).
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has been identified. This small, recombinant protein has the
potential to detect trypanosome infections directly on blood
smears and to become the molecular recognition unit in an
immuno-toxin design for trypanosomosis therapy.
The reasons to prefer camel single domain antibody for this
type of application is dictated by: (i) the small size of the
antibody-fragment (19), and (ii) the density of the VSG mole-
cules on the surface of the African trypanosomes exposing their
hypervariable immunogenic areas and hiding the conserved
epitopes of VSG dimers (13–15) (Fig. 5). From calculations of
the number and size of VSG molecules and the total surface of
the parasite it has been estimated that the VSG molecules
should nearly contact each other (8, 33–35). This level of den-
sity is modeled in Fig. 5 where the crystallographic structure of
the N-terminal part of the VSG dimer (Protein Data Bank code
2VSG) is viewed along its widest or narrowest side. (To com-
pensate for the remaining 130 amino acids of which structural
details are lacking, we duplicated the structure of the last 130
amino acids of the VSG and rotated it over 180° before adding
it to the rest of the structural VSG model to obtain a more
faithful representation of the actual VSG volume and VSG
density on the coat of the parasite.) The hypervariable region of
the VSG molecule is located at the top of these VSG models,
whereas the Asn-linked carbohydrate is attached to the lower
part of the molecule (within the red part in Fig. 5), deeply
buried between the VSG molecules. The concanavalin-A lectin
binds to the VSG sugars; however, this tetrameric molecule can
only interact specifically with the carbohydrates exposed in the
flagellar pocket (28). The same carbohydrates of the VSGs
located on the remaining parasite surface are inaccessible for
molecules of this size, as illustrated by Fig. 5. In the same vein,
a monoclonal antibody against the carbohydrate moiety of the
VSG, or even a Fab derived from such a monoclonal, is expected
to be occluded from the carbohydrate in the trypanosomal coat.
In contrast, a dromedary single domain antibody should gain
an easier access to epitopes close to the membrane, cryptic for
larger molecules, due to its smaller overall size (problate par-
ticle of 2.8 nm diameter and height of 4.4 nm).
It could be argued that the size-restricted access of some
conserved VSG epitopes on parasites can be overcome as well
with a Fv, the smallest antigen-binding fragment of a conven-
tional antibody. However, these molecules are twice as large
compared with the VHH molecules. In addition, the Fv frag-
ments are unstable entities that need a synthetic tether be-
tween the VH and VL domains to arrive at a single chain Fv or
disulfide-stabilized Fv. Quite often, the linker provokes single
chain Fv dimerization, and the disulfide-stabilized Fv frag-
ments are more difficult to express in large quantities (36). For
these reasons, the Fv constructs seemed less favorable for the
envisaged application.
The further reason to choose dromedary antibodies lies in
their recognition of epitopes that are less immunogenic for
conventional antibodies. This feature was originally demon-
strated by the large number of enzyme inhibiting HCAbs or
VHHs present in serum of an immunized dromedary or in the
pool of enzyme-specific VHHs (20). A structural explanation for
this observation was provided by crystallographic analyses of
VHHs complexed to their cognate antigens (32, 37, 38). A
protruding loop of the lysozyme-specific VHH inserts in the
cavity of the active site of the enzyme (27, 32). Protruding
antigen-binding loops are rare in conventional antibodies,
whereas VHHs have usually an extended complementary de-
termining region 3 (CDR3) sequence, suggesting that protrud-
ing loops might occur frequently in VHHs (19). In another case,
a binder with shorter CDR sequences was also able to interact
with the substrate-binding pocket of amylase because the en-
tire domain could insert in this groove on the enzyme surface
(37). Such convex epitopes are definitely less antigenic for
conventional antibodies. Hence, it seems that VHHs prefer a
convex epitope, or cavities on the antigenic surface, whereas
conventional antibodies associate preferably on flat surfaces
(19, 38). The differential targeting between HCAbs and conven-
tional antibodies was confirmed with the serum immunoglobu-
lins of the dromedary immunized with AnTat 1.1. Only the
IgG3 HCAbs recognized AnTat 1.1, MITat 1.1, and MITat 1.5,
reflecting the presence of cross-reacting antibodies. Most likely,
these cross-reacting antibodies interact with an epitope that is
common to AnTat 1.1 and at least one other VSG subclass. The
FIG. 4. Survival of bloodstream-form T. brucei AnTat 1.1 and
MITat 1.5. The percentage of surviving parasites in presence of various
amounts of PDM toxin (dotted line, ƒ) or CCM prodrug (dotted line, Œ)
were recorded to determine the LD50. For prodrug therapy, parasites
were incubated with VHH::lactamase fusion (cAb-Lys3::-lactamase
() or cAb-An33::-lactamase (f)), washed to remove unbound conju-
gate, and incubated with various amounts of CCM. The number of
surviving parasites was scored after 3 h. The experimental setup was
repeated for MITat 1.5 parasites with cAb-An33 fusion protein ().
FIG. 5. Model of coat-penetrating potential of single domain
antibody fragments. The structure of the VSG dimer (green and blue)
shown from its widest (two molecules on the left) or narrowest sides
(two molecules on the right), the red part represents the 130 amino
acids for which no structure is available yet. The glycosylation site is
present within this part. The structure of concanavalin-A (top-right,
space filling with sugar-binding pockets in yellow), a Fab fragment
(top-left ribbon representation; VH, red; VL, orange; CH1 and CL,
black), and the structure of a VHH in gray with the antigen-binding
loops in yellow are given. All structures are drawn to scale and the
density of the VSG (shown unilateral) is as calculated in Ref. 35.
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cAb-An33 could be the VHH of such a pan-reactive HCAb as it
recognizes the conserved carbohydrate of the VSG.
The sugar specificity of cAb-An33 was amply demonstrated
by concanavalin-A competition, by inhibition of TNF-
trypanolysis, by recognition of various proteolytic peptides
containing the Asn-linked high mannose oligosaccharide
(GlnNAc2-Man5–9), by direct association with a synthetic oligo-
mannose-9, and by a greatly reduced interaction with deglyco-
silated AnTat 1.1. In accordance with our model predictions,
this binder could attach to its epitope present within the living
parasites. Moreover, the high specificity for the trypanosomal
sugar moiety, and the conservation of this epitope on various
serotypes warrants the efficacy of cAb-An33 to detect trypano-
somes directly in blood smears. Remarkably, the chemical cou-
pling of small FITC groups on the VHH didn’t lead to detrimental
obstruction of the epitope targeting. Although parasites express-
ing other VSG classes might exhibit a reduced accessibility of the
epitope, possibly resulting from an altered VSG packing density
or from the presence of additional or extended VSG loops.
To obtain a cAb-An33-derived therapeutic agent for treat-
ment of trypanosomosis it will be necessary to link an effector
molecule to this small molecular recognition unit. As a proof of
concept we chose the -lactamase as fusion partner because of
its multiple attractive features. First, it is a well characterized,
small monomeric molecule of 30 kDa that is expressed success-
fully in prokaryotic (39) and eukaryotic cells. Second, it can be
fused efficiently via its N-terminal end to the C-terminal end of
a VHH, because the C-end and the antigen-binding loops of the
antibody fragment are on opposite sides of the domain, and the
N-terminal of the enzyme is distant from the catalytic site.
Third, the enzyme has excellent catalytic properties for chro-
mogenic substrates (e.g. nitrocefin) as well as cell-permeable
fluorescent substrates (coumarin cephalosporin fluorescein) al-
lowing a sensitive screening (40). Moreover, the enzyme can
convert the CCM prodrug into a potent toxic PDM (26), so that
the fusion can be used in an antibody directed antibody pro-
drug therapy. Fourth, the lactamase activity is absent in
eukaryotic host cells, and finally, sensitive complementation
tests are under development (41). The experiments with cAb-
An33::-lactamase on trypanosomes are very promising. Ap-
parently, the antibody moiety of the conjugate is still able to
detect the parasites, while preserving the nitrocefin hydrolyz-
ing activity of the attached enzyme. For diagnostic purposes,
this fusion product can be used in combination with nitrocefin
to detect as low as 5 parasites/ml, a sensitivity that is compa-
rable to the most sensitive, modern detection techniques for
trypanosomosis (42, 43). In addition, the potential to eliminate
the parasites with the same conjugate in a prodrug therapy
with CCM was positively evaluated.
We surmise that the successful employment of single domain
antibody derivatives to combat trypanosomosis could also be
repeated to tackle various other infectious agents exhibiting
any form of antigenic variation (1–4) because the basis for their
success relies on their general properties: the small size and
the capacity to recognize non-conventional epitopes of the vari-
able component that become cryptic for larger antibodies when
incorporated into the micro-organism.
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